Nasal delivery offers many benefits over traditional approaches to vaccine administration.
Nasopharynx-Associated Lymphoid Tissue (NALT)

86
The NALT can be simply defined as organized mucosal immune system in the nasal mucosa 87 that consist of lymphoid tissue, B cells, T cells and antigen presenting cells (APCs) and are 88 covered by an epithelial layer containing memory (M) cells. 16 M cells are present in the 89 epithelial cell layers and have specialization in transporting antigen across the 90 epithelium. 17, 18 91 92 Whenever the nasal mucosa is exposed to pathogens or antigenic substances, the intruder 93 will interact with the mucosal immune system. The type of interaction is highly dependent 94 on the characteristics of the antigen. The pathogen or immunogenic substances may be able 95 to pass through the nasal epithelium and interact with the APCs such as macrophages and 96 DCs. These APCs will process the antigen and migrate to the lymph node where the 97 immunogenic portion will be presented to the T cells. This marks the activation of the 98 immune response cascade. A soluble antigen might be recognized by the APCs, 19 while 99 particulate antigen is generally taken up by the M cells and transported to the NALT. 20 The 100 NALT is also drained to the lymph node where further antigen processing will occur. A 101 schematic representation of this process in more detail mechanisms is presented in Figure   102 3 21 .
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In addition to the MALT, the mucosal immune system also produces the antibody 107 immunoglobulin A (IgA), that plays an important role in mucosal immunity at mucosal 108 surfaces. 22 IgA constitutes up to 15 % of the total immunoglobulin, which is predominantly IL-17F and IL-21. It Is known that the Th-17 family of cytokines respond to extracellular 154 bacterial and fungal pathogens, and Th-17 cells enhance generation of Th-1 cells through an 155 increased IFN-g activation giving rise to a Th-1/Th-17 immune response that activates 156 macrophages and other innate responses. [36] [37] [38] Stimulation of epithelial cells by the Th-17 157 family of cytokines can aid tissue repair and secretion of antimicrobial peptides, which can 158 exert a protective effect in pulmonary infection. 39 There is contradictory evidence, however, 159 regarding the role of Th-17 response in nasal immunization. Early work on the role of Th 160 polarization in nasal immunization indicated that this route always promotes a Th-17 161 response. 40 Later research has indicated that the response is more nuanced, with some 162 contradictory evidence regarding advantages and disadvantages of IL-17A induction. 41, 42, 43 163 Predominance of one set of cytokines over the other is generally indicative of polarization of 164 Th responses, for example the presence of IL-4 and absence of IFN-γ indicate a classical Th-2 165 polarized immune reaction 44 although these cytokines can also be released at the same 166 time. 45, 46, 47 The varying cytokine profiles related to CTL and antibody production are 167 fundamental in affording protection against a specific pathogen. Specific macrophage 168 activation was found to play a crucial role in the eradication of Mycobacterium tuberculosis 169 bacterial infections, 48 showing that the induction of specific immune responses may play a 170 key role in determining whether a given vaccine product is effective.
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The recently discovered innate lymphoid cells (ILCs) act as an early source of cytokines to 173 regulate and direct mucosal immune responses. 49 Unlike B or T cells, however, they do not 174 exhibit antigen specificity. Group 1 ILCs (ILC1s) include NK cells and produce Th-1 type 175 cytokines IFN-γ and tumor necrosis factor-α (TNF-α ); group 2 ILCs (ILC2s) produce Th-2 type 176 cytokines IL4, IL-5 and/or IL-13, while group 3 ILCs (ILC3s) include lymphoid tissue inducer 177 cells that produce Th-17 type cytokines IL-17 and/or IL-22. Both ILC1s and ILC3s have been 178 implicated in type 1 and Th17 cell-mediated immunity and disease. 50 Because they are 179 involved in early release of cytokines at mucosal sites, ILCs have been implicated in directing 180 immune response at the mucosal surface, as shown by a number of recent studies. 51, 52 NK 181 cells and ILC1-like cells damped the immune response after vaginal administration of 182 ovalbumin and cholera toxin to mice. 53 NK cells have been shown to enhance Th 183 proliferation through IFN-γ production, 54 while ILC2s play a role in directing Th-2 response. 55
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There is also evidence that ILCs can act as APCs, although this may be specific to the 185 lymphoid tissue site involved and is thought to occur to a lesser extent than through the 186 professional APCs. 55 Finally the regulatory T-cells (Tregs) play a role in ILC and Th communication, 54 as well as helping to directly control Th response, which is particularly 188 important in autoimmune dysfunction discussed later. 56
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Advantages of nasal vaccine delivery
191
The nasal route has great potential for vaccination due to the organized immune systems of While much of the work on nasal vaccine delivery is currently focused on prophylactic 209 vaccines, the access that the nasal route provides to the mucosal immune system also has 210 relevance for therapeutic vaccines used to treat rather than prevent disease. Nasal 211 immunotherapy for treatment of various cancers and Alzheimer's are currently generating 212 much interest. 63,64 A particular focus is the use of therapeutic vaccines for the treatment of 
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The autoimmune and inflammatory response is governed by regulatory T-cells (Tregs), with 219 poor function or reduced numbers of Tregs being associated with autoimmune disease.
220
Treatments for this family of diseases are often non-specific, or use immune suppressants 221 that increase susceptibility to infection. Development of effective therapeutic vaccine would 222 correct the inappropriate immune response through generation of tolerance to the self-223 antigen(s). 65 Treg cells that express the forkhead box P3 transcription factor are known as
224
FoxP3+T-cells, with dysfunction of this subset of Tregs being implicated in a range of chronic 225 inflammatory disorders. 66 It has long been known that oral delivery is effective in generating 226 antigen tolerance, through deliberate introduction of the antigen to food. 67 More recently it 227 has been shown that a similar tolerance induction can be achieved via nasal delivery through 228 activation of the DCs in the draining lymph nodes to enhance induction of FoxP3+T-cells. 68
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Examples of successful nasal delivery include immunization to suppress atherosclerosis 69, 70 230 and arthritis. 71 The effect of adjuvant on tolerance is discussed in a later section.
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Formulation approaches 233 Current nasal formulations include, solutions (drops or sprays), powders, gels and solid 234 inserts. 72 Solutions are often described in the literature as they are both the easiest way of 235 formulating a vaccine for an in vivo study or clinical trial, and are the easiest to administer 236 for example in mice where the liquid is often pipetted directly into the nostril. In humans 237 this often means that the subject either has to remain laying down or with their head held 238 back for a period of time after administration, which is not realistic in a mass vaccination 239 setting. Sprays are easier to administer and deliver vaccine further into the nasal cavity, but may still leak out of the nostril or drip into the oral cavity. Including a gelling agent in the 241 formulation that is either mucoadhesive or able to penetrate through mucus offers 242 increased residence time, while advantages of solid formats such as powders or solid inserts 243 include ease of manufacture and stability, while liquids are more prone to degradation.
244
Taste may also be a factor as formulations may travel into the oral cavity, although given 245 that vaccines tend to be administered once or twice only, this is less of an issue than for 246 medicines that are taken on a regular basis. Currently there is more evidence to support the hypothesis that particles smaller than 300 300nm are the most effective at crossing mucus, 103 but there is also evidence to suggest 301 that larger particles are also able to penetrate. Results from intranasal administration of 302 mucoadhesive microparticles suggest that penetration of the entire particle may not be 303 necessary to induce an immune response. 104 
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Data published from a study using the Russian intranasal vaccine showed better herd 360 immunity for intranasal LAIV than inactivated vaccine. 127 Herd immunity is a crucial impact 361 of mas vaccination programs; it is the immunity given to the whole population, even those 362 who have not received a vaccine, because enough of the population (the herd) have 363 received the vaccine that the infection cannot effectively spread. However, it should be 364 noted that the Russian LAIV is administered in 2 doses 3 weeks apart, which increases cost 365 and has the possibility of reducing compliance.
366
Targeting school age children for influenza has two benefits, first this age group tend to have 
399
ChiSysâ , that achieved good success in a clinical trial for a Norovirus vaccine. 137 Because of 400 the proprietary and often pre-approval nature of the devices described (with the exception 401 of Flumist/Fluenz and MAD Nasal), there is a paucity of information regarding design of 402 some of the devices described in this section. The interested reader is referred to the 403 relevant company web-sites (Table 2) , which will offer more current information than is 404 possible in this review. 
